Fenofibrate Cuts Residual Risk in Statin Users

Fenofibrate Cuts Residual Risk in Statin Users

An elevated low-density lipoprotein cholesterol (LDL-C) level is a major risk factor for cardiovascular disease (CVD), and several randomised clinical trials have shown that lowering LDL-C levels with statins results in a substantial reduced CVD morbidity and mortality. However, a significant number of treated patients continue to experience events, despite targeting LDL-C levels according to current guidelines. Moreover, even upon high doses of statins, a substantial residual risk remains.

Modern Medicine – Issue 4 2021